To further assess the effect of K187 mutant of GPX2 on TKI resistance, we generated human CRC cells in which GPX2 had been knocked out by CRISPR/Cas9 (HCT15-KO) to perform the following rescue experiments. This evidence concerns the gene GPX2 and colorectal carcinoma.